Home / Market News / $PEN
benzinga Corporate Catalyst Impact 92/100 ● negative

Penumbra Q2 EPS $0.88 Misses $1.20 Estimate, Sales $390.046M Beat $389.009M Estimate

Jul 30, 2026, 9:03 PM UTC · Primary ticker $PEN

Penumbra reported Q2 earnings per share that significantly missed analyst estimates, indicating weaker profitability than expected. However, the company's sales exceeded expectations and showed strong year-over-year growth, suggesting robust demand for its products despite the earnings shortfall.

Penumbra's Q2 earnings report reveals a mixed performance. The substantial miss on EPS, down 23.48% year-over-year, is a significant concern for investors, indicating potential issues with cost management or margins. This could lead to short-term negative pressure on the stock as profitability is a key metric. Conversely, the sales beat and 14.89% year-over-year sales growth demonstrate strong underlying business momentum and demand for Penumbra's medical devices, which is a positive long-term indicator. Traders will likely focus on the EPS miss in the short term, but the strong sales figures could provide a floor for the stock if the company can address its profitability challenges.

$PEN negative Significant EPS miss despite sales beat
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.